ConductScience.org, home

Paper41438749

Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.

Yengo CK and 17 others. Front Immunol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations. Papers, record 41438749. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41438749

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-02-19
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yengo CKClauvis Kunkeng
2Liu XXiaomei
3Laghlali GGabriel
4Park SCSeok-Chan
5Klingler JJéromine
6Luo CCChristina C
7Jiang XXunqing
8Kong XPXiang-Peng
9Rao PGPriyanka G
10Upadhyay CChitra
11Wiest MJMatthew J
12Muramatsu HHiromi
13De Geest BGBruno G
14Wong PTPamela T
15Tam YYing
16Pardi NNorbert
17Schotsaert MMichael
18Hioe CECatarina E

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AIDS VaccinesMajor topic
HIV AntibodiesMajor topic
env Gene Products, Human Immunodeficiency VirusMajor topic
HIV-1Major topic
HIV InfectionsMajor topic
Antibody FormationMajor topic
Animals
Mice
Mice, Inbred BALB C
Female
Adjuvants, Immunologic
Antibodies, Neutralizing
Humans
Nanoparticles
Immunoglobulin G

Source PubMed

Download CSV of topics

Grants11

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R21 AI176069NIAID NIH HHSUnited StatesR21AI176069PubMed and NIHNIH RePORTER
P01 AI172531NIAID NIH HHSUnited StatesP01AI172531PubMed and NIHNIH RePORTER
IK6 BX004607BLRD VAUnited StatesIK6BX004607PubMed and NIHNIH RePORTER
I01 BX005616BLRD VAUnited StatesI01BX005616PubMed and NIHNIH RePORTER
R01 AI148327NIAID NIH HHSUnited StatesR01AI148327PubMed and NIHNIH RePORTER
R01 AI179427NIAID NIH HHSUnited StatesR01AI179427PubMed and NIHNIH RePORTER
R01 AI139290NIAID NIH HHSUnited StatesR01AI139290PubMed and NIHNIH RePORTER
R01 AI145655NIAID NIH HHSUnited StatesR01AI145655PubMed and NIHNIH RePORTER
R01 AI160706NIAID NIH HHSUnited StatesR01AI160706PubMed and NIHNIH RePORTER
R01 AI140909NIAID NIH HHSUnited StatesR01AI140909PubMed and NIHNIH RePORTER
R21 AI180874NIAID NIH HHSUnited StatesR21AI180874PubMed and NIHNIH RePORTER

Download CSV of grants

References75

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133370382Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes.PLoS Pathog2020https://conductscience.org/library/papers/33370382PubMed
224352234Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.Nature2014https://conductscience.org/library/papers/24352234PubMed
333761206Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.N Engl J Med2021https://conductscience.org/library/papers/33761206PubMed
425368619IgG subclasses and allotypes: from structure to effector functions.Front Immunol2014https://conductscience.org/library/papers/25368619PubMed
539489918Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.Mol Ther2024https://conductscience.org/library/papers/39489918PubMed
628472280Diversification of IgG effector functions.Int Immunol2017https://conductscience.org/library/papers/28472280PubMed
733554060Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.iScience2021https://conductscience.org/library/papers/33554060PubMed
828678869V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.PLoS One2017https://conductscience.org/library/papers/28678869PubMed
931845904Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination.J Clin Invest2020https://conductscience.org/library/papers/31845904PubMed
1033087466Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.J Virol2020https://conductscience.org/library/papers/33087466PubMed
1136119058Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.Front Immunol2022https://conductscience.org/library/papers/36119058PubMed
1226497511Mouse and human FcR effector functions.Immunol Rev2015https://conductscience.org/library/papers/26497511PubMed
132693365Biological role of different antibody classes.Int Arch Allergy Appl Immunol1989https://conductscience.org/library/papers/2693365PubMed
1432142167Antibody-mediated complement activation in pathology and protection.Immunol Cell Biol2020https://conductscience.org/library/papers/32142167PubMed
1529514914Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.J Virol2018https://conductscience.org/library/papers/29514914PubMed
1633801906Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env.Vaccines (Basel)2021https://conductscience.org/library/papers/33801906PubMed
1724504509Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.PLoS One2014https://conductscience.org/library/papers/24504509PubMed
1829408873Mouse IgG2c Fc loop residues promote greater receptor-binding affinity than mouse IgG2b or human IgG1.PLoS One2018https://conductscience.org/library/papers/29408873PubMed
191636090Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major.Science1992https://conductscience.org/library/papers/1636090PubMed
2032491861Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus.Mol Pharm2021https://conductscience.org/library/papers/32491861PubMed

See all 75 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41438749

GET https://conductscience.org/api/papers/v1/41438749/references?page=2